BI-4732 is an orally active, reversible, ATP-competitive EGFR inhibitor with blood-brain barrier penetration. BI-4732 inhibits the kinase activity of EGFR L858R, T790M and C797S with IC50 values of 1 nM while sparing EGFR wild-type. BI-4732 inhibits EGFR and reduces the phosphorylation of AKT, ERK, and S6K. BI-4732 demonstrates excellent intracranial anti-tumor efficacy in YU-1097 xenograft model harboring EGFR_E19del/T790M/C797S. BI-4732 can be used for the study of non-small cell lung cancer (NSCLC)[1].
Molecular Weight:
592.69
Purity:
99.30
CAS Number:
[2769715-68-4]
Formula:
C32H36N10O2
Target:
Akt,EGFR,ERK,Ribosomal S6 Kinase (RSK)
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
